Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cronos Group Inc (CRON) vs Visa Inc (V) Price & Performance

Cronos Group IncTrade

Price performance (Past 24H)

Key statistics

Cronos Group Inc vs Visa Inc — how do they compare? Cronos Group Inc trades at $3.08 (market cap $1.11B), while Visa Inc trades at $362.79 (market cap $668.96B). The key difference: Visa Inc is far larger — about 602.7× Cronos Group Inc's market cap, and Visa Inc pays a 0.74% dividend while Cronos Group Inc pays none. Which is the better fit depends on your goals.

CRONV
Market Cap
$1.11B$668.96B
Sector
HealthFinancials
52-Week High
$3.27$370.47
52-Week Low
$2.30$295.52
Enterprise Value
$310.67M$679.54B
Volume
10,431,336
Dividend Yield
0.74%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cronos Group Inc

CRON trades at $3.10 with a 0.98% daily gain, showing bullish technical momentum. The company delivered strong Q2 2026 results with 58% YoY revenue growth and earnings beat, while maintaining #1 market share in Canadian vapes and edibles. Despite negative net income in 2025, revenue growth accelerated to $147M with improving margins. Technical indicators show bullish moving averages but RSI suggests potential overbought conditions near $3 resistance.

Outlook remains positive with international expansion and European cannabis legalization driving growth, though competitive pressures and execution risks persist. Analyst consensus is mixed with 60% hold ratings, reflecting cautious optimism about CRON's turnaround trajectory from previous losses to projected 39% profit margin by 2026.

Visa Inc

Visa (V) trades at $361.32, down 0.33% on the day, with strong fundamentals including 50.78% net income margin and consistent earnings beats. The stock shows bearish technical signals but maintains bullish moving averages. Recent developments include AI-powered commerce initiatives and stablecoin partnerships, positioning Visa for future payment system evolution. Financial trends show revenue growth from $29.3B in 2022 to $40B in 2025, with robust cash flow generation.

Visa presents a compelling long-term investment with 85% analyst buy ratings and $426.31 consensus price target suggesting 18% upside. Key risks include fintech competition and regulatory pressures, but the company's dominant market position, high profitability, and innovation in digital payments support continued growth potential.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cronos Group Inc

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.

Read more on CRON

About Visa Inc

Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.

Read more on V